Mankind Pharma agrees €48 million acquisition of 70% stake in Armed Cell Therapeutics to enter CAR-T oncology
Mankind Pharma has agreed to acquire a 70% stake in Belgium's Armed Cell Therapeutics for €48 million, marking its entry into next-generation CAR-T oncology therapies.
The transaction, conducted through Mankind Pharma's Netherlands subsidiary, will provide a majority interest in Armed Cell Therapeutics and its investigational cell therapy programmes for cancers including non-Hodgkin lymphoma and small-cell lung cancer.
The investment expands Mankind's strategic focus into advanced oncology treatments and provides exposure to emerging CAR-T approaches, including research into generating CAR-T cells directly within the body.
Field | Content |
Article Type | Deals |
Companies | Mankind Pharma; Armed Cell Therapeutics |
Deal Type | Majority stake acquisition agreement |
Acquirer | Mankind Pharma through its Netherlands subsidiary |
Target | Armed Cell Therapeutics |
Target Country | Belgium |
Equity Stake | 70% |
Transaction Consideration | €48 million |
Transaction Status | Definitive acquisition agreement announced |
Therapeutic Modality | Chimeric antigen receptor T-cell therapies |
Therapeutic Areas | Oncology; non-Hodgkin lymphoma; small-cell lung cancer |
Technology Focus | Next-generation CAR-T therapies including investigational in vivo CAR-T approaches |
Development Stage | Investigational programmes |
Geography | India; Netherlands; Belgium |
What Happened | Mankind Pharma agreed to acquire a 70% stake in Armed Cell Therapeutics for €48 million. |
Why It Matters | The transaction marks Mankind Pharma's strategic entry into advanced cell therapies and adds investigational oncology assets to its development interests. |
Strategic Rationale | Mankind seeks to diversify into next-generation cancer treatments through a controlling investment in a specialised European biotechnology company. |
Potential Impact | The acquisition could support development of CAR-T approaches for haematological and solid-tumour indications if investigational programmes advance successfully. |
Key Takeaway | Mankind Pharma has agreed to invest €48 million for a majority stake in Armed Cell Therapeutics to establish a position in CAR-T oncology. |
What to Watch | Transaction completion, pipeline disclosures, preclinical and clinical milestones, and progress in in vivo CAR-T development. |
Primary Source | Mankind Pharma |
Relevant Date | 15 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments